Study of Quality of Life in Adults With Chronic Lymphocytic Leukemia Treated With Acalabrutinib in France Using PLATON Database Data

What this Trial Is About

Chronic lymphocytic leukemia CLL is the most common leukemia in adults, with most patients diagnosed over 51 years old. This study evaluates the quality of life QoL of CLL patients treated with acalabrutinib in a real-life setting in France. It aims to describe patients QoL from treatment start up to 12 months, addressing a gap as QoL has rarely been assessed in real-world studies, especially for acalabrutinib treatment. The study is retrospective and observational, using data from the PLATON national cohort that tracks patients with hematological cancers, including CLL. It focuses on patients who are treatment-nave and started acalabrutinib, either alone or with obinutuzumab. Data are collected at treatment initiation and quarterly up to one year, including QoL questionnaires EORTC QLQ-C30 and QLQ-CLL17 and treatment adherence using the GIRERD grid. No additional visits or interventions are required beyond routine care. Participants have their clinical and demographic data recorded in the PLATON database, with quality control measures ensuring data accuracy. Researchers analyze QoL changes over time, symptom levels, treatment patterns, and adherence. The study plans to include about 120 patients and follows them for 12 months after starting acalabrutinib. All data comes from existing records, with no direct patient interventions or extra assessments.

AQUALIS:QoL of CLL Patients Treated With Acalabrutinib in France, Retrospective Study Based on Data From PLATON Database